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Prostate cancer is the second most common cancer and leading cause of cancer death in 
men. It is caused by malignant growth of the prostate gland. The largest risk factor is 
age, but it has one of the lowest fatality rates among cancers and most patients die of 
other causes. Prostate cancer is usually diagnosed together with high prostate specific 
antigen level. It can be treated with radio- or hormonal therapy depending how far the 
cancer has progressed. However, sometimes the cancer progresses to a stage where it is 
resistant to the treatment and will eventually lead to death.  
 
Histochemistry is the study of chemical components in tissues. In this thesis, the objec-
tive was to use three types of stainings to study goblet cell metaplasia and the expres-
sion of peptidase inhibitor 15 (PI15) in mouse prostate tissue. The purpose was to assess 
goblet cell metaplasia in aged and miR-32 transgenic mouse prostate tissue and to estab-
lish a protocol for staining of PI15. Haematoxylin-eosin staining was used to find areas 
of interest, which were then further stained with periodic acid-Schiff (PAS) staining to 
detect goblet cells by the mucin they secrete. For staining of peptidase inhibitor 15, an 
immunohistochemical protocol was established. PI15 is a gene in a family of secretory 
proteins expressed in some glandular structures, such as the prostate.  
 
In the tissues studied here, goblet cell metaplasia was found by the mucin inside the 
goblet cells and some by the mucin they secrete to the lumen inside the gland. The met-
aplasia could also be seen in the epithelial cells, which were taller than average. The 
metaplasia was located in the ventral and dorsal lobes of the tissue, close to the urethra, 
and often in several glands rather than just one, which indicated that the metaplasia had 
spread. No difference was found in the metaplasia between transgenic and wild type 
mouse prostate tissues. To further study the metaplasia, more tissue samples should be 
examined to see where exactly it is located, as well as to study the metaplasia in human 
prostate tissue.  
 
PI15 was expressed in the tissues and no large difference was found between the two 
fixatives tested. PAXgene fixation did show slightly better results in the whole tissue 
samples, which could be caused by the cross-linking formalin fixation causes. In addi-
tion, two different buffers were tested to optimise antigen retrieval. The buffers showed 
a larger difference and PI15 was better visible in the pH 9 buffer. In the future, also 
transgenic mouse prostate and human prostate should be tested with staining of PI15 to 
see whether PI15 has a role in prostate cancer development. 
Key words: prostate cancer, immunohistochemistry, peptidase inhibitor 15, PI15, goblet 
cell 
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Eturauhassyöpä on miesten toiseksi yleisin syöpä ja aiheuttaa eniten syöpäkuolemia 
miehillä. Syöpä johtuu eturauhasen pahanlaatuisesta kasvusta ja vanhemmilla miehillä 
on iän takia suurempi riski sairastua eturauhassyöpään. Eturauhassyövällä on kuitenkin 
yksi alhaisimmista kuolleisuuksista ja suurin osa sairastuneista kuolee muiden syiden 
takia. Eturauhassyöpä diagnosoidaan usein prostataspesifisen antigeenin korkealla ar-
volla. Sitä voidaan hoitaa säde- tai hormonihoidolla riippuen siitä, kuinka pitkälle syöpä 
on edennyt. Osa syövistä etenee kuitenkin vaiheeseen, jossa syöpä jatkaa leviämistä 
hoidoista huolimatta johtaen lopulla kuolemaan.  
 
Histokemia on kudosten kemiallisten komponenttien oppi. Opinnäytetyön tavoitteena 
oli kolmea värjäystekniikkaa apuna käyttäen tutkia pikarisolujen metaplasiaa ja pepti-
daasi-inhibiittori 15 (PI15) ekspressiota hiiren eturauhaskudoksessa. Tarkoituksena oli 
arvioida pikarisolujen metaplasiaa vanhoissa ja miR-32-transgeenisissä hiiren eturau-
haskudoksissa ja kehittää värjäysprotokolla PI15:lle. Hematoksyliini-eosiini-värjäystä 
käytettiin kiinnostavien kudosten löytämiseen, joita sitten värjättiin perjodihappo-
Schiff-värjäyksellä pikarisolujen löytämiseksi niiden erittämän musiinin avulla. Pepti-
daasi-inhibiittori 15:n värjäykseen kehitettiin immunohistokemiallinen värjäysmenetel-
mä. PI15 on geeni sekretoristen proteiinien perheessä, joka ekspressoituu rauhasraken-
teissa, esimerkiksi eturauhasessa.  
 
Tutkituissa kudoksissa pikarisolumetaplasia löydettiin pikarisolujen erittämän musiinin 
avulla, joko itse solujen sisältä tai rauhasonteloista. Metaplasia voitiin myös havaita 
epiteelisoluissa, jotka olivat korkeampia kuin normaalisti. Metaplasia sijaitsi kudoksen 
ventraali- ja dorsaalilohkoissa, virtsaputken lähellä, ja usein useammassa kuin yhdessä 
rauhasessa. Tämä osoitti metaplasian levinneen. Transgeenisten ja villityyppien välillä 
metaplasiassa ei huomattu eroavaisuutta. Jatkossa metaplasiaa voitaisiin tutkia useam-
missa kudosnäytteissä, jotta voitaisiin selvittää, missä se tarkalleen sijaitsee, sekä tutkia 
metaplasiaa ihmisen eturauhaskudoksessa. 
 
PI15 oli ekspressoitu kudoksissa ja suurta eroavaisuutta ei löydetty kahden testatun fik-
satiivin välillä. PAXgene-fiksaatiolla saatiin hieman parempia tuloksia kokokudosnäyt-
teissä, mikä saattaa johtua formaliinin aiheuttamasta silloittamisesta. Lisäksi testattiin 
kahta eri puskuria antigeenin paljastuksen optimointiin. Puskureissa näkyi suurempi 
eroavaisuus: PI15 näkyi paremmin pH 9-puskuria käytettäessä. Tulevaisuudessa myös 
transgeenisten hiirten sekä ihmisten eturauhaskudoksia tulisi testata PI15-värjäyksellä, 
jotta voitaisiin selvittää, onko PI15:llä roolia eturauhassyövän kehityksessä.  
  
Asiasanat: eturauhassyöpä, immunohistokemia, PI15, peptidaasi inhibiittori 15, pika-
risolu 
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ABBREVIATIONS 
 
 
ADT Androgen deprivation therapy 
AR Androgen receptor 
BPH Benign prostatic hyperplasia 
CRISP Cysteine-rich secretory proteins 
CRPC Castration resistant prostate cancer 
DAB 3,3α-diaminobenzidine tetrahydrochloride  
FFPE Formalin fixation and paraffin embedment 
HRP Horseradish peroxidase 
H&E Haematoxylin eosin  
IgG Immunoglobulin G 
IHC Immunohistochemistry 
NBF Neutral buffered formalin 
PAS  Periodic acid-Schiff 
PCLC Paneth cell-like change 
PFPE PAXgene fixation and paraffin embedment 
PIN Prostatic intraepithelial neoplasia 
PI15 Peptidase inhibitor 15 
PSA Prostate-specific antigen 
TNM Tumour, lymph node and metastasis category based prostate 
cancer classification system 
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1 INTRODUCTION 
 
 
Prostate cancer is malignant growth of the prostate gland. It is the most common cancer 
in men after skin cancer and the second leading cause of death from cancer in men. The 
largest risk factor is age as the occurrence rises radically after the age of 55. One in ten 
men will get prostate cancer at some point in their lives. The PSA test has however 
made it possible to detect prostate cancer early. (Kellokumpu-Lehtinen, Joensuu & 
Tammela 2013, 562–563.) 
 
The objective of this thesis is to study goblet cell metaplasia in mouse prostate tissue, as 
well as to establish a protocol for one possible biomarker. The purpose is to examine 
goblet cell metaplasia with the help of periodic acid-Schiff staining in aged and trans-
genic mouse prostate tissue. Periodic acid-Schiff staining detects mucin, which is nor-
mally not secreted by the prostate. The second purpose is to establish a protocol for de-
tecting peptidase inhibitor 15 by immunohistochemistry in mouse prostate tissue.  
 
This study is carried out for the Molecular Biology of Prostate Cancer group in Prostate 
Cancer Research Center in the Institute of Biosciences and Medical Technology (Uni-
versity of Tampere) for postdoctoral fellow Leena Latonen. Professor Tapio Visakorpi 
leads the group. There are seven different research groups in Prostate Cancer Research 
Center all with a common goal, which is to find answers regarding the etiology of the 
disease, the identification of clinically relevant diseases, personalised cancer therapy, 
and new treatments for the disease (University of Tampere 2015). 
 
7 
 
2 THEORETICAL BACKGROUND 
 
 
2.1 Prostate cancer 
 
2.1.1 Prostate 
 
The prostate is a walnut-sized accessory sex gland of the male reproductive system. Its 
main function is to produce an alkaline fluid that is a part of the seminal fluid. It is lo-
cated below the bladder, surrounding the urethra. The prostate can be divided into four 
zones: anterior, central, transitional, and peripheral, as can be seen in figure 1. 
(O’Rourke & Loughrey 2004, 311; Pawlina & Ross 2011, 808–809; Kujala 2012, 800.) 
 
 
FIGURE 1. Prostatic zones (Koivukoski 2015, adapted from O’Rourke & Loughrey 
2004, 312) 
 
The central zone surrounds the ejaculatory ducts and forms approximately 25 % of the 
prostate gland. Its histological features differ from the rest of the prostate: it is more 
similar to the ejaculatory ducts and seminal vesicles, whereas the rest of the prostate 
gland derives from the urogenital sinus. The central zone is resistant to pathological 
abnormality, and tumours originating from it have very different behaviours and out-
comes than tumours originating from other zones. (O’Rourke & Loughrey 2004, 311; 
Pawlina & Ross 2011, 809; Vargas et al. 2012.) 
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The peripheral zone, which is formed around the central zone, contains around 70 % of 
the glandular tissue. 80-90 % of adenocarcinomas originate from the peripheral zone, 
which is also prone to inflammation. The glands in this zone are small and simple. The 
anterior fibromuscular stroma is located in the front surface of the prostate gland, and it 
is mainly composed of smooth muscle fibers and very few glands. (O’Rourke & 
Loughrey 2004, 311; Pawlina & Ross 2011, 809–810; Kellokumpu-Lehtinen et al. 
2013, 563.) 
 
The transitional zone, which surrounds the urethra, forms approximately 5 % of the 
prostatic glandular tissue, and contains mucosal glands. This region often undergoes 
hyperplasia as the man ages. It can cause problems in urination due to its close proximi-
ty to the urethra. This condition, called benign prostatic hyperplasia (BPH), is very 
common in elderly men. (O’Rourke & Loughrey 2004, 311; Pawlina & Ross 2011, 809; 
Kujala 2012, 802.) 
 
 
2.1.2 Metaplasia and goblet cells 
 
Metaplasia is the change from one adult cell type to another. It is often benign at first, 
but can sometimes develop into malignancy and cancer if affected cells continue to 
grow and spread. Metaplasia is found in 0.6 % of prostates. There are many types of 
metaplasia in the prostate, the most common being urothelial and squamous metaplasia. 
Other more rare types of metaplasia found in the prostate include mucinous and Paneth 
cell-like metaplasia. (Harik & O’Toole 2012; Bostwick, Qian & Hossain 2014, 403; 
Kumar et al. 2014, 38; Trpkov 2014, 58.) 
 
Urothelial metaplasia is also known as transitional metaplasia, as it often occurs in the 
transitional zone of the prostate, in cells that line the urethra. It can also be found in the 
peripheral zone. Urothelial metaplasia is the replacement of benign epithelium or pe-
ripheral ducts and acini with benign urothelium (cells lining the urethra). Its location 
varies widely, making it sometimes difficult to identify it from small biopsy samples. 
(Humphrey 2008, 379; Harik & O’Toole 2012; Bostwick et al. 2014, 407; Trpkov 2014, 
58.) 
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Squamous metaplasia is when the normal prostatic epithelium is replaced with benign 
squamous epithelium. It often lacks malignant atypia. Squamous metaplasia usually 
occurs in normal prostatic glands, but is also found in prostates treated with hormonal or 
radiation therapy, or adjacent to prostatic infarct. (Humphrey 2008, 379; Harik & 
O’Toole 2012; Bostwick et al. 2014, 404; Trpkov 2014, 58–59.) 
 
Mucinous metaplasia is the replacement of epithelial cells with mucin-secretory cells, 
such as goblet cells. The cells have basal nuclei and the cytoplasm is filled with mucin. 
Mucinous metaplasia is usually focal and it can involve a varying number of acini from 
individual cells to even clusters. (Humphrey 2008, 379; Bostwick et al. 2014, 405–406; 
Trpkov 2014, 58.) 
 
Paneth cell-like metaplasia or change (PCLC) is a microscopic cellular alteration to neu-
roendocrine cells (cells that receive neuronal input and release message molecules to the 
blood) with large, eosinophilic (stain with eosin) granules. They usually appear as iso-
lated cells or in clusters. This type of change is often linked with a good prognosis as 
most cancers with PCLC are not aggressive. PCLC is very rare in prostatic adenocarci-
nomas, and is instread more common in its subtype, ductal adenocarcinoma of the pros-
tate. (Humphrey 2008, 379; Lee, Miller & Epstein 2010; Mortal et al. 2010; Bostwick et 
al. 2014, 404, 406–407; Trpkov 2014, 59–61.) 
 
Goblet cells are unicellular, mucin-secreting glands that appear in mucinous metaplasia. 
The mucins are high molecular weight, large glycoproteins. The structure of a goblet 
cell can be seen in figure 2. The cell is shaped like a glass goblet with mucinogen gran-
ules at the apex of the cell and a stem-like basal portion. The basal portion contains the 
nucleus, mitochondria, Golgi apparatus, and endoplasmic reticulum. The microvilli are 
on the surface of the cell. (Pawlina & Ross 2011, 589, 592–593; Kim & Khan 2013.) 
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FIGURE 2. Structure of a goblet cell (Koivukoski 2015, adapted from Pawlina & Ross 
2011, 593) 
 
Goblet cells are components of the mucosal epithelia in the gastrointestinal tract, the 
airways, and the conjunctival epithelium in the eye. There they produce mucin to main-
tain a stable environment in the tissue due to external fluctuations. Mucins are used as 
lubrication in all three tissues, but have further tissue-specific functions: mucus pro-
vides a bacteria-free environment in the small intestine, protects the respiratory epitheli-
um in the airways, and is a component of tears in the eye. (Kim & Khan 2013; 
McCauley & Guasch 2015.) 
 
 
2.1.3 Cancer background and causes 
 
Prostate cancer is the most common cancer in men in Finland and the second most 
common cause of death among cancers. Over 98 % of prostate cancers are adenocarci-
nomas, which are defined as neoplasia formulating in epithelial cells with a glandular 
origin. In addition to prostate adenocarcinoma, there are also other types of cancer that 
can occur in the prostate, such as ductal adenocarcinoma, urothelial cancer, squamous 
cell cancer and mucinous cancer. These are all however extremely rare, some making 
up only less than 1 % of all prostate carcinomas. Lymphomas or leukaemia can some-
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times initiate from the prostate, as well as secondary tumours from other organs. 
(O’Rourke & Loughrey 2004, 315; Kujala 2012, 800, 803–804; Marcus et al. 2012; 
Kellokumpu-Lehtinen et al. 2013, 563.)  
 
There are many known risk factors in prostate cancer. The most common factor is age: 
two thirds of prostate cancers are found in men over 65 years old, while it is rare in men 
under 50. There are also large differences between different ethnic groups in the inci-
dence of prostate cancer. A genetic variant found in higher frequencies in men of Afri-
can American descent has been found to be associated with prostate cancer. There are 
also studies showing that lifestyle, nutrition, and physical exercise are linked with the 
risk of prostate cancer. (Damber & Aus 2008; Kujala 2012, 804.) 
 
Prostate adenocarcinoma has one of the lowest fatality rates among cancers, and it has a 
5-year survival rate of almost 99 % in the United States. Approximately 15 % of men 
will be diagnosed with prostate cancer at some point in their lives. The median age at 
diagnosis is 66 and 80 at death. Most men, however, die of causes other than prostate 
cancer. (VanderWeele 2014; SEER 2015.) 
 
 
2.1.4 Diagnosis  
 
Prostate cancer can be tested with a prostate-specific antigen (PSA). PSA is a protein 
produced in the prostate gland, and it is released into the blood in abnormal conditions 
in the prostate structure. The normal PSA level is under 4.0 ng/ml but it rises with age. 
The PSA test has become very common in recent years, and its development has made 
it possible to detect prostate cancer much earlier. This has, however, also resulted in the 
increasing treatment of clinically insignificant prostate cancers and overdiagnosis. On 
average, PSA levels start increasing approximately seven years before the cancer has 
progressed to a clinical state. PSA is specific to the prostate but not prostate cancer. 
Some benign diseases, such as BPH, also release PSA into the blood, hence an in-
creased PSA level does not always mean prostate cancer. (O’Rourke & Loughrey 2004, 
313; Damber & Aus 2008; Lilja, Ulmert & Vickers 2008; Shen & Abate-Shen 2010; 
Kujala 2012, 804; National Cancer Institute 2012; Kellokumpu-Lehtinen et al. 2013, 
565; Sfoungaristos, Katafigiotis & Perimenis 2013.) 
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Those found with high PSA levels are advised to get a biopsy from which a diagnosis 
can be made. Multiple biopsies are taken and they are graded with a Gleason score. The 
two most common histological patterns in the biopsy samples are graded from 1 to 5, 
with 5 being the most aggressive form. The worst grade should always be included. The 
result is a Gleason score from 2 to 10, the most common scores being 6 and 7. (Damber 
& Aus 2008; Shen & Abate-Shen 2010; Kellokumpu-Lehtinen et al. 2013, 563.) 
 
TNM staging is also used in the classification of prostate cancer. It is based on three key 
points: primary tumour (T), lymph nodes (N), and distant metastasis (M). The tumour is 
categorised from 0 to 4, depending on the size and growth. Lymph nodes and metastasis 
are categorised as either 0 or 1, with 0 indicating that there is no spreading to lymph 
nodes or distant metastasis, and 1 indicating that there is. The TNM stage, PSA level, 
and Gleason score are used to determine the stage (from I to IV) of the cancer. The 
stage grouping categories and requirements can be seen below in table 1. (Kellokumpu-
Lehtinen et al. 2013, 564–565; American Cancer Society 2015.) 
 
TABLE 1. Stage grouping in prostate cancer (American Cancer Society 2015) 
Stage tumour lymph nodes metastasis 
Gleason 
Score 
PSA 
(ng/l) 
I 
1 0 0 ≤ 6 < 10 
2a 0 0 ≤ 6 < 10 
IIa 
1 0 0 7 < 20 
1 0 0 ≤ 6 10 - 20 
2a or 2b 0 0 ≤ 7 < 20 
IIb 
2c 0 0 any any 
1 or 2 0 0 any ≥ 20 
1 or 2 0 0 ≥ 8 any 
III 3 0 0 any any 
IV 
4 0 0 any any 
any 1 0 any any 
any any 1 any any 
 
 
2.1.5 Cancer progression and treatment 
 
Prostate cancer is considered to be a multifocal cancer where there are multiple tumours 
in one organ. The cancer can originate from several different cells in the prostate. The 
progression of prostate adenocarcinoma can be seen below in figure 3. The normal pros-
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tatic epithelium has two basal layers: basal cells and basal lamina. Throughout the can-
cer progression, both of these layers are lost partially or completely, depending on how 
far the cancer progresses. (de Werra et al. 2008, 129; Shen & Abate-Shen 2010.) 
 
 
FIGURE 3. Cancer progression (Koivukoski 2015, adapted from Abate-Shen & Shen 
2000; Shen & Abate-Shen 2010) 
 
Prostatic intraepithelial neoplasia (PIN) is often said to be a precursor of prostate ade-
nocarcinoma. It is characterised as prostate epithelial hyperplasia. PIN has two different 
stages: low grade and high grade. The only way to diagnose PIN is to take a biopsy as it 
does not raise PSA levels or have any macroscopical changes. (O’Rourke & Loughrey 
2004, 313; Shen & Abate-Shen 2010; Kujala 2012, 808.) 
 
Latent prostate adenocarcinoma is defined as a cancer that is not active and does not 
show clinical symptoms. Clinical adenocarcinoma is a cancer, which has progressed to 
the stage where the tumour can be clinically found. Latent adenocarcinoma has been 
found in men in their 20s, 30s and 40s even though prostate cancer is extremely rare in 
younger men. These results suggest that cancer initiation can start at a relatively early 
age, but it does not develop into a cancer until at a later age. Most studies say that latent 
prostate cancer is an early stage of prostate cancer. The tumours found in latent prostate 
cancers are often Gleason score 1-4, very rarely 5, and the growth rate is slower. In clin-
ical cancers, the tumours are often Gleason scores 2 to 5. (Takahashi et al. 2006; Shen 
& Abate-Shen 2010.) 
 
There are many different treatment options for prostate cancer. For localised or latent 
prostate cancer, it is sometimes best to not treat it at all and instead to actively monitor 
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the cancer progression. The latter is often the most suitable option, especially when the 
patient has a life expectancy of less than 10 years and the test results do not change. 
(Damber & Aus 2008; Shen & Abate-Shen 2010; National Cancer Institute 2015.)  
 
Other treatment options for localised prostate cancer (stages I-IIb) are radical prostatec-
tomy and radiotherapy. In radical prostatectomy, the entire prostate, including the tu-
mour, is surgically removed. Radical prostatectomy has been found especially useful in 
patients under 65, and it is often performed only when the disease is curable and the 
patient has a life expectancy of more than 10 years. On the contrary, radiotherapy is 
used when surgery is not suitable, and it can be used either by itself or alongside with 
other treatments when the cancer has progressed to a higher stage. (O’Rourke & 
Loughrey 2004, 316; Kellokumpu-Lehtinen et al. 2013, 566–569.) 
 
Androgen deprivation therapy (ADT) is also a commonly used treatment method in 
prostate cancer. Androgen receptor (AR) is a nuclear hormone receptor, which is acti-
vated by androgenic hormone binding. It is essential to normal prostate and prostate 
cancer development. In the beginning of prostate cancer, the cells are very dependent on 
testosterone, so when the androgen is deprived, the cells start apoptosis, which is why 
the treatment is very efficient. It is also the most common and effective treatment meth-
od for metastatic prostate cancer. There are different ways of performing the treatment 
and all of them have various side effects. (Montgomery et al. 2008; Shen & Abate-Shen 
2010; Jalava et al. 2012; Kellokumpu-Lehtinen et al. 2013, 570–571; Latonen 2014.) 
 
Prostate cancer often metastasises to the bone. Other common sites include the lung, the 
liver, and the pleura. In the bone, it forms characteristic osteoblastic (bone forming) 
lesions. Metastatic prostate cancer is often treated with many treatment methods, ADT 
for multiple months and a short period of radiotherapy in the end, for example. (Logo-
thetis & Lin, 2005; Shen & Abate-Shen 2010; Kellokumpu-Lehtinen et al. 2013, 575.)  
 
Prostate cancer is defined as castration resistant when the cancer keeps progressing even 
though castration (ADT) has been performed. Castration resistant prostate cancer 
(CRPC) occurs in 80 % of the patients with metastasised prostate cancer. It is more ag-
gressive and androgen-independent, meaning the AR signalling pathway still works and 
the cancer progresses. CRPC is incurable and will eventually lead to death. At this 
stage, patients often only receive treatment to relieve pain caused by the bone metasta-
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sises. (Jalava et al. 2012; Kellokumpu-Lehtinen et al. 2013, 576–577; Yuan et al. 2013; 
Latonen 2014; Saad & Miller, 2015.) 
 
 
2.1.6 Peptidase inhibitor 15  
 
Peptidase inhibitor 15 (PI15) is a member of the CRISP (cysteine-rich secretory pro-
teins) family. CRISPs function as venoms or toxins in some plants, insects, and verte-
brates. They are expressed in human secretory glands, such as reproductive, salivary, 
and thyroid glands. The PI15 gene is expressed in mouse and human prostate tissue, 
skeletal and smooth muscle, ovaries and aortic wall. (Smith et al. 2001; Gibbs, Roelants 
& O’Bryan 2008; Falak et al. 2014; NCBI 2015.) 
 
PI15 might have a role in the drug resistance regulation in ovarian cancer, therefore it 
could serve as a potential target in targeted therapies. One study found out that PI15 
interacts with 11 genes, 5 of which are oncogenes, which could further indicate a role 
for it in cancer. (Zou et al. 2015.) In addition, PI15 expression was detected in the 
chicken during organogenesis, which might mean it also has a role in the development 
of internal organs (Falak et al. 2014). PI15 is also a part of the trypsin inhibitor family. 
It has been reported that this family’s proteases have a role in gynaecological cancers, 
but no further mechanistic studies or therapeutic strategies have been developed. (Giri et 
al. 2014.) 
 
PI15 is secreted and localized in the extracellular matrix in multiple species, therefore it 
might have a role in the regulation of the modification of the extracellular matrix. There 
are studies showing an increased production of PI15 in cancer cell lines and weak tryp-
sin inhibitory activity, which could mean the PI15 has a role in cancer pathogenesis. 
However, neither of these theories has yet to be confirmed. (Gibbs et al. 2008.) 
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2.2 Histology of mouse prostate 
 
In contrast to human prostate, which is a single structure, the mouse prostate is divided 
into four lobes: ventral, dorsal, lateral, and anterior. Three of these lobes can be seen in 
figure 4 below. The dorsal lobe surrounds the urethra. The ventral lobe is located above 
the urethra, in between the lateral prostate lobes. The anterior lobes are located cranial 
to the other lobes, curving upwards along the seminal vesicles. The mouse prostate has 
less stroma than the human prostate. The glands are irregularly shaped and surrounded 
by the connective tissue. (Knoblaugh & True 2011, 296–300.) 
 
 
FIGURE 4. Histology of mouse prostate (Latonen 2014, modified) 
 
Dorsal lobe has small or moderate glands, dense stroma, and eosinophilic secretion. The 
epithelium is columnar, and the nuclei are basally or centrally located. Lateral prostate 
has sparse infoldings in the epithelium, the secretion is pale and amorphous, and the 
stroma is thin. The epithelium is more cuboidal and the nuclei are more basal than in the 
dorsal prostate. Ventral prostate reminds of lateral prostate, but it has larger glands. In 
addition, the secretions are homogenous and paler than in the lateral prostate. 
(Knoblaugh & True 2011, 296–300; Latonen 2014.)  
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2.3 Histochemistry 
 
Histochemistry is the study of chemical components in tissues. Histochemical methods 
maintain the whole structure of the tissue, meaning both the localization and the cells 
can be studied. It uses an array of different methods, such as staining and light micros-
copy. There are many different staining methods, which highlight different components 
of the tissue and cell: nucleus, various enzymes, and extracellular components for in-
stance.  (Pawlina & Ross 2011, 1–5; Thermo Fisher Scientific 2015.) 
 
Histological staining is based on a chemical procedure in the tissue, such as specific 
binding or enzymatic activity. (Pawlina & Ross 2011, 3.) Before the tissues can be 
stained and studied further, they must be processed. The processing steps can be seen in 
figure 5 below.  
 
 
FIGURE 5. Sample processing steps 
 
 
2.3.1 Tissue processing 
 
The most common tissue processing protocol is formalin-fixed and paraffin embedded 
(FFPE) tissue blocks. The purpose of fixation is to stop enzyme activity and metabo-
lism, while still preserving the morphology of tissue samples. The most commonly used 
chemical fixative is 10 % neutral buffered formalin (NBF) with a pH of 7.0. 10 % NBF 
fixes the tissues by penetrating the tissue and forming cross linkages between the reac-
fixation
dehydration
clearing
embedding
microtomy
staining
mounting
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tive glycol and proteins. (Cook 2006, 11, 13–14; Colley & Stead 2013, 21, 23; Human 
Protein Atlas 2015.) 
 
Another tissue processing protocol option is PAXgene fixation and paraffin embedment 
(PFPE). The fixation is a commercial fixation kit by PreAnalytiX (Switzerland). It has 
two containers: the fixative, which contains methanol, acetic acid, and a soluble organic 
compound, and the stabilising solution, which contains different alcohols, such as etha-
nol. It is currently researched whether or not PFPE is a better option than FFPE. PFPE 
is meant to improve the preservation of morphology, nucleic acids and proteins better 
than FFPE but it is much more expensive. (Kap et al. 2011; Belloni et al. 2012; PreAna-
lytiX 2015.) 
 
There are other chemical fixative solutions, such as different alcohols and acetic acid. 
All these, however, have different qualities that make them not as suitable for histo-
chemistry, such as price or toxicity and tissue swelling, shrinking or hardening. In addi-
tion to chemical fixation, heat, microwaves or ultrasound technology can be used, with 
or without chemical solutions. Chemical fixation is, however, the most common fixa-
tion protocol used in histology. The used fixation method is chosen according to what is 
needed from the tissue sample and, for example, which cellular components are being 
studied.  (Cook 2006, 12–17; Colley & Stead 2013, 24–25; Rhodes 2013, 70–71.) 
 
During tissue processing, wax is used to replace fixation reagents containing water. This 
is done in two stages: dehydration and clearing. Dehydration removes the water by 
slowly diffusing the water out and replacing it with the solvent used in dehydration. It is 
done in multiple steps by increasing the solvent concentration all the way up to abso-
lute. Clearing clears the alcohol out of the tissue sample and replaces it with the solvent, 
which has to be miscible with the wax. (Cook 2006, 22–24, 26; Colley & Stead 2013, 
25.) 
 
After the clearing, the solvent is replaced with molten wax (melting point 50-60 °C). 
The solid wax has a similar hardness to tissues, which supports the tissue both internally 
and externally. Once the processing is done, the tissues are embedded in paraffin blocks. 
The tissue remains stable in the blocks, which can be easily handled and stored for 
many years without deterioration. (Cook 2006, 21–23, 29–30; Colley & Stead 2013, 
25.) 
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The blocks are cut into 3-10 µm sections using a microtome. The sections cut are float-
ed in room temperature water and picked up to glass slides. After this, the sections are 
floated in warm water (around 5-9 °C cooler than the wax melting point), which allows 
the sections to fully expand and straighten to the original dimensions. When the sections 
have dried off of excess water, they are heated in an incubator from 2 to 16 hours in 
over 37 °C to achieve complete adhesion. (Cook 2006, 36–37, 40–41; Rolls 2010, 19–
20; Colley & Stead 2013, 25; Human Protein Atlas 2015.) 
 
After the adhesion, the wax in the tissues must be completely removed so all the rea-
gents, antibodies, and probes can adhere to the tissue. This is done by immersing the 
slides in a dewaxing solution, such as xylene or hexane. After this, the dewaxing agent 
is removed and replaced with water by gradually decreasing the alcohol content. (Colley 
& Stead 2013, 25–26.) 
 
 
2.3.2 Staining methods 
 
Haematoxylin-eosin staining (H&E) is the most widely used staining technique for 
histological samples because of its ability to widely demonstrate different types of 
structures. There are many different ways of preparing the haematoxylin solution, but 
all of them have the same main purpose: to stain the nuclei blue. Eosin is used as a 
counterstain and it stains the cytoplasm, as well as most connective tissues, pink or red-
dish. (Cook 2006, 226–227; Bancroft & Layton 2013, 173.) 
 
Haematein is the oxidation product of haematoxylin and it is a natural dye that is re-
sponsible for the staining. Haematein is anionic, but with the presence of a mordant, it 
has a positive charge and so it can be bound to the anionic sites of the nuclei. There are 
dozens of different haematoxylin solutions, but the most common ones used in H&E 
staining are alum based. These stain the nuclei red, but when subjected to a weak alkali 
solution, they gradually convert to blue. (Bancroft & Layton 2013, 174.) 
 
Eosin is used to show the general architecture of a tissue. If differentiated properly, it 
can be used to distinguish different types of cells and connective tissues. Eosin, which is 
a xanthene dye, can be found in multiple different types, the most common one being 
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eosin Y. It is used as a 0.5-1 % solution in distilled water. Tap water is used for further 
differentiation with eosin. (Bancroft & Layton 2013, 173.) 
 
Periodic acid-Schiff staining (PAS) is used to detect molecules with a high carbohy-
drate content including mucin, fungi, and glycogen. It is the most important technique 
on detecting carbohydrates due to its ability to detect most of the neutral saccharide con-
taining materials. The PAS technique is a two-step staining protocol with two chemical 
reactions: an oxidation reaction with periodic acid, and a reaction with Schiff’s reagent. 
It is used to detect whether a cell is PAS-negative or -positive. (Cook 2006, 112–113; 
Bisen 2014, 357.)  
 
The periodic acid acts as an oxidising agent: it creates dialdehydes from carbohydrates. 
Periodic acid (HIO4) is used as a 0.5 or 1 % aqueous solution. It is the most commonly 
used oxidising agent in PAS staining since it does not continue oxidising after the crea-
tion of aldehydes. The dialdehydes are then exposed to Schiff’s reagent, which creates 
an insoluble magenta compound. Schiff’s reagent is very sensitive and specific to alde-
hydes; even ketones do not react with it in PAS method. Haematoxylin is often used as 
a counterstain and it stains the nuclei blue. (Cook 2006, 113–114; Bisen 2014, 357.) 
 
 
2.3.3 Immunohistochemistry 
 
Immunohistochemistry (IHC) is a protocol where an immunological reaction is used to 
identify antigens in tissue samples. In immunoperoxidase methods, antibody binds to an 
enzyme, which then creates an insoluble coloured substance. This, with the help of a 
countestain, can then be used for highly specific immunohistochemistry when specific 
antibodies are used. The staining protocol steps for IHC are shown in figure 6 below. 
(Cook 2006, 188; Jackson & Blythe 2013, 382.) 
 
 
FIGURE 6. IHC staining process (Koivukoski 2015) 
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Fixation sometimes alters the structure of the antigens, but most of these changes are 
reversible. In FFPE tissue samples, antigen retrieval is needed to undo the crosslinking 
between some molecules to recover the antigens for the antibodies to bind to. This is 
done with heat, enzymes or a combination of these two. All of these treatments break 
down the crosslinks in antigens. Endogenous peroxidases are blocked with a solution, 3 
% hydrogen peroxidase or a commercial blocking solution for example, to avoid back-
ground staining. (Chen, Cho & Yang 2010; Jackson & Blythe 2013, 390–391; Taylor 
2013, 12; Human Protein Atlas 2015.) 
 
Antibodies, also known as immunoglobulins, are found in blood and tissue fluids. They 
are part of the immune system, and they are produced in B-lymphocytes and plasma 
cells when a foreign structure is detected. The produced antibodies invade foreign struc-
tures by binding to them strongly. There are many types of antibodies, but the most 
common ones used in immunohistochemistry are immunoglobulin G (IgG). (Cook 
2006, 180; Jackson & Blythe 2013, 390–391.) 
 
Antibodies can be polyclonal or monoclonal. Polyclonal antibodies are produced in an-
imals, whereas monoclonal can be produced in cell culture. Polyclonal antibodies are a 
heterogeneous mix of antibodies and they will bind to multiple different epitopes. They 
are more likely to create at least some kind of background noise, but they also have a 
higher chance of binding to the target molecule. Monoclonal antibodies bind to a specif-
ic epitope and they are more identical as they only contain one antibody. The staining 
results of polyclonal antibodies can vary due to their heterogeneity, but monoclonal 
antibodies produce a more uniform staining. (Cook 2006, 182–183; Jackson & Blythe 
2013, 384; Human Protein Atlas 2015.)   
 
The primary antibody binds to the specific antigen of interest, while the secondary anti-
body binds to the primary antibody. The secondary antibody is often labelled with an 
enzyme, which produces the coloured product when incubated with a suitable chromo-
gen. The most commonly used enzyme is horseradish peroxidase (HRP) because it 
works well with a common chromogen, DAB (3,3α-diaminobenzidine tetrahydrochlo-
ride). DAB forms an insoluble brown substrate in the presence of a peroxidase. Haema-
toxylin is often used as a counterstain. (Jackson & Blythe 2013, 382, 384–385; Taylor 
2013, 12; Vector Laboratories 2014.) 
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3 AIM OF THE STUDY 
 
 
The objective of the study is to assess goblet cell metaplasia and to establish a protocol 
for a possible biomarker in mouse prostate tissue. The results will benefit prostate can-
cer research from a histochemical angle: whether the biomarker has a role in prostate 
cancer and how the goblet cells act histologically.  
 
The purpose of this study is to examine goblet cell metaplasia in aged and miR-32 
transgenic mouse prostate tissue by performing periodic acid-Schiff staining to detect 
mucin not normally secreted by the prostate. The second purpose is to test and validate 
an immunohistochemistry protocol to detect PI15 in mouse prostate tissue.  
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4 MATERIALS AND METHODS 
 
 
4.1 Sample preparation 
 
There were two types of samples used in this study: wild type and miR-32 transgenic 
mouse prostate. The samples were received fixed and in their embedding cassettes. 
Most of the samples were fixed in 10 % NBF (FF-Chemicals) for 2 to 14 days, with the 
average being 3 to 4 days. The remaining selected samples were fixed with PAXgene™ 
Tissue Containers (Qiagen). PAXgene™ samples were fixed in a mixture of methanol 
and acetic acid for 5 to 7 hours and then stabilised in ethanol for 5 days. After fixation, 
all the samples were processed in Shandon Citadel 2000 tissue processor. FFPE and 
PFPE samples were processed separately. The protocol used in the processing of both 
fixatives is shown in table 2. More information about the solutions used in tissue pro-
cessing can be found in appendix 1.  
 
TABLE 2. Sample processing protocol 
solution t (h) 
70 % EtOH 2 
96 % EtOH 1.5 
96 % EtOH 1 
Absolute EtOH 1.5 
Absolute EtOH 1.5 
Absolute EtOH 1.5 
Xylene 1.5 
Xylene 1.5 
Xylene 1.5 
Paraffin (59 °C) 1.5 
Paraffin (59 °C) 1 - 
 
After the tissues were processed, the cassettes were moved from the molten paraffin to 
the Sakura Tissue-Tek® TEC™ Tissue embedding console for embedding. The samples 
were embedded so that the urethra was facing upwards in the mold. The sample was 
then covered in molten paraffin, the cassette placed on top of it, and then placed on a 
cold plate (– 4 °C) in order for the wax to set. When the wax had set, the molds were 
removed and the samples stored in + 8 °C until sectioning. 
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The sectioning was done with three different microtomes, a rotation microtome Leica 
RM2235 which was used to cut 7 µm sections, and two sliding microtomes, Leica 
SM2010 R and Leica SM2000 R, which were used to cut 5 µm sections. From each 
sample, the entire prostate was sectioned. Three sections were placed on one Super-
frost® Plus slide by floating them in room temperature distilled water. The sections 
were then straightened in + 52 °C distilled H2O and placed in an upright position to dry 
out the excess water overnight. After drying, the slides were incubated in + 62 °C from 
2 hours to overnight.  
 
 
4.2 Histochemical stainings 
 
From the slides prepared, every third one was H&E stained with Kedee KD-RS3 Slide 
Stainer using the protocol showed in table 3. The rest of the slides were stored in  
+ 8 °C. After the slides were stained, coverslips were added to the slides using a Dako 
Coverslipper by putting the slides soaked in xylene to the coverslipper. The bubbles 
underneath the coverslip were gently pushed out to avoid interference during microsco-
py. DPX mountant medium (VWR) was used as a mounting medium.  
 
TABLE 3. H&E staining protocol 
solution t (min) 
n-Hexane 3 
n-Hexane 3 
Absolute EtOH 2 
Absolute EtOH 1 
96 % EtOH 2 
70 % EtOH 1 
distilled H2O 30 sec 
Mayer’s Haematoxylin 6 
H2O 7 
distilled H2O 40 sec 
Eosin 1 
H2O 1 
distilled H2O 30 sec 
96 % EtOH 2 
Absolute EtOH 2 
Absolute EtOH 2 
Absolute EtOH 2 
Xylene 2 
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From the H&E staining results, selected slides were chosen for PAS staining. The stain-
ing was done by hand using the protocol shown below in table 4. The periodic acid so-
lution was prepared by dissolving 1.00 g of periodic acid into 200 ml of water. The re-
maining of the solutions used in this process were commercial (Appendix 1). The slides 
were then covered using the same protocol as in H&E staining.  
 
TABLE 4. PAS staining protocol 
solution t (min) 
n-Hexane 4 
n-Hexane 4 
Absolute EtOH 2 
96 % EtOH 2 
70 % EtOH 2 
distilled H2O 1 
0.5 % Periodic Acid 5 
distilled H2O 30 sec 
Schiff's reagent 7 
H2O 5 
Mayer’s Haematoxylin 1 
H2O 5 
distilled H2O 1 
70 % EtOH 2 
96 % EtOH 2 
Absolute EtOH 2 
Xylene 2 
Xylene 2 
 
 
4.3 Immunohistochemical stainings 
 
Suitable slides were chosen for staining with PI15 antibody. First, the slides were de-
paraffinized using the protocol shown in table 5. After deparaffinization, the slides were 
air dried and put in a slide chamber with buffer solution for antigen retreival. Two dif-
ferent buffers were tested: pH 9 Tris-EDTA buffer and pH 6 Citrate buffer (Appendix 
2). Both chambers were placed in 2100 Retriever, which heats them up to 121 °C for 2 
minutes in high pressure, and then gradually cooled down to room temperature. The 
buffer solutions are replaced with 1x TBS Tween to keep them from drying when 
placed in the Autostainer. 1x TBS Tween was diluted 1:10 from 10x TBS Tween (Ap-
pendix 2).  
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TABLE 5. Deparaffinization 
solution t (min) 
Hexane 4 
Hexane 4 
Absolute EtOH 1 
 
After the antigen retrieval, the slides were immunostained using Lab Vision™ Auto-
stainer 480. The protocol used in the staining was created using old antibody staining 
protocols for various different antibodies, which have been found suitable. The protocol 
can be seen in table 6. Each slide was treated with 300 µl of each reagent except for 
washes where the slides were washed thoroughly. Anti-PI15 (OriGene) was diluted with 
Normal Antibody Diluent (ImmunoLogic) by first making a 1:100 dilution and from 
that a 1:10 dilution. DAB was diluted by adding 15 µl of ImmPACTTM DAB Chromo-
gen (Vector Laboratories) concentrate to every 1 ml of ImmPACTTM DAB Diluent 
(Vector Laboratories). More information about the solutions used with the autostainer 
can be found in appendix 1. 
 
TABLE 6. PI15 staining protocol 
solution t (min) wash 
TBS Tween - 1x 
3 % H2O2 5 - 
TBS Tween - 1x 
anti-PI15 1:1000 30 - 
TBS Tween - 3x 
UIP Max  30 - 
TBS Tween - 3x 
ImmPACTTM DAB 5 - 
distilled H2O - 2x 
TBS Tween - 1x 
Mayer’s Haematoxylin 2 - 
TBS Tween - 1x 
distilled H2O - 1x 
 
After the immunostaining, the slides were rinsed quickly in distilled water, and dehy-
drated using the protocol shown in table 7. The slides were then covered with coverslips 
using the same protocol as for H&E staining.  
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TABLE 7.  Dehydration  
solution t (min) 
70 % EtOH 2 
96 % EtOH 2 
Absolute EtOH 2 
Xylene 4 
Xylene 4 
 
All the stained slides (H&E, PAS and IHC) were scanned with an Olympus BX51 mi-
croscope. First, the entire slide was scanned with an Olympus Plan N 4x objective to 
detect all the parts with tissue. Then, the scanner would determine and focus 3 to 6 fo-
cus points in each tissue sample with a 20x magnification using Olympus UPlan Apo 
20x objective. After all the focus points had been focused, the scanner would scan the 
tissue samples with the 20x objective.  
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5 RESULTS 
 
 
5.1 Goblet cell metaplasia 
 
All the stained slides were studied and examined for goblet cells. Goblet cells can be 
found by the mucin they secrete. In each of the figures 7 and 8 we can see two different 
samples, one sample is H&E and the other PAS stained. Both figure 7 sections are from 
a wild type mouse prostate, while the figure 8 ones are from a transgenic mouse pros-
tate. The left columns in both figures are H&E stained and right columns PAS stained, 
with the bottom ones being larger magnifications of the rectangles shown in the top 
row. In figure 9, we can see PAS stainings of two different sections of the same tissue 
with approximately 250 µm of tissue separating them. All of the three samples shown 
are processed with FFPE protocol. 
 
In the H&E stainings in figures 7C and 8C, the white arrows are pointing to a slightly 
lighter shade of pink than the cell cytoplasm which is the mucin inside the goblet cells. 
In the larger magnification in figure 8C, the goblet cells can be seen very clearly. In the 
PAS staining, the mucin the goblet cells secrete makes the lumen inside the epithelial 
cells much darker than average, which makes finding the goblet cells in PAS stained 
samples much easier. This can be seen in figures 7B and 8B (black arrows versus white 
arrows). Goblet cells can be seen in figures 7D and 8D as well as in both 9A and 9B 
(black arrows). The mucin inside the goblet cells is stained deep purple, therefore it dif-
fers from the normal epithelial cells, which are just different shades of blue. 
 
In figures 7C and 9B, the metaplasia can be seen in the change of the cell size. The grey 
arrow in figure 7C is showing much shorter cells than the black arrows. The whole epi-
thelium, when compared to the two top glands, is also much thinner in the bottom 
gland. The nuclei are much taller and oval shaped in the upper glands, whereas in the 
bottom gland they are mostly round. The same can be seen in figure 9B: the epithelium 
is much taller in the upper part of the gland (black arrows) when comparing to the lower 
part of the gland and the gland on the left (white arrows). This metaplasia becomes very 
clear in figure 7D, in which the top two glands have much darker lumen and much more 
goblet cells in the epithelium than in the bottom gland, in which only a few light purple 
spots can be seen in the epithelium.  
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FIGURE 7. Histological stainings of a wild type mouse prostate (FFPE, 18 months) A. 
H&E staining, and B. PAS staining of a whole mouse prostate with 20x magnification. 
C. H&E staining, and D. PAS staining of a mouse prostate with 360x magnification 
30 
 
 
FIGURE 8. Histological stainings of a transgenic mouse prostate (FFPE, 23 months) A. 
H&E staining, and B. PAS staining of a whole mouse prostate with 22x magnification. 
C. H&E staining, and D. PAS staining of a mouse prostate with 540x magnification 
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FIGURE 9. PAS staining of a transgenic mouse prostate (FFPE, 23 months) with 240x 
magnification. The difference between the sections in A and B is approximately 250 µm 
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5.2 Peptidase inhibitor 15 expression 
 
For staining of PI15, only a necessary number of samples were stained, one for each 
buffer from both fixating-techniques. The whole sections can be seen in figure 10. The 
top row was fixed using the FFPE method and the bottom row was fixed using the 
PFPE method. In both cases, the left column has pH 9 Tris-EDTA buffer used in anti-
gen retrieval, whereas the right column has pH 6 Citrate buffer. A larger magnification 
of the rectangles shown in figure 10 can be seen in figure 11.  
 
In figure 10, it is very difficult to see any difference at all between 10A and 10B. There 
is a slight difference in the lumen shown with the black arrows, as in 10A it is slightly 
darker than in 10B in some glands. The white arrows are however showing that the lu-
men in 10B would be a bit darker than in 10A. This could either be caused by the buff-
ers used for antigen retrieval or, because the difference is so small, simply due to the 
fact that the sections are from a slightly different part of the prostate and the lumen has 
a different density in that part.  
 
In 10C and 10D, the difference can be seen very clearly. 10C is much darker overall and 
clearly showing the PI15 expression all over the tissue, whereas in 10D it is only visible 
around the urethra (white arrows) as well as in some of the glands close to the urethra. 
The black arrows in 10C and 10D show us the larger difference between the two buff-
ers, with 10C showing us almost completely brown glands, with a slight tint to blue, 
whereas the glands in 10D are almost completely stained with haematoxylin.  
 
In figure 11, the difference in PI15 expression can be seen more clearer in both 11A and 
11B as well as 11C and 11D, when compared to figure 10. The expression of PI15 can 
be seen lining the muscle layer in 11A (black arrow), whereas it cannot be seen in 11B. 
The epithelial cells in both 11A and 11B (white arrows) are both stained with DAB, 
with the 11A ones being a slightly darker shade.  
 
In 11C and 11D the difference is again larger. The connective tissue and the fibromus-
cular stroma are stained in both 11C and 11D (black arrows). The white arrows, which 
show us the epithelial cell lining in 11C, show us that it’s stained almost throughout the 
gland, whereas this cannot be seen in 11D at all.  
 
33 
 
 
FIGURE 10. Immunohistological stanining of PI15 of a whole mouse prostate. A-B. 
FFPE, wild type (11 months) C-D. PFPE, wild type (15 months) A, C. pH 9 Tris-EDTA 
Buffer. B, D. pH 6 Citrate buffer.  
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FIGURE 11. Immunohistological stanining of PI15 of a mouse prostate with 400x 
magnification. A-B. FFPE, wild type (11 months) C-D. PFPE, wild type (15 months) A, 
C. pH 9 Tris-EDTA Buffer. B, D. pH 6 Citrate buffer. 
 
35 
 
6 DISCUSSION 
 
 
The objective of this study was to assess goblet cell metaplasia and to establish a proto-
col for one biomarker in mouse prostate tissue. The purpose of this study was to exam-
ine goblet cell metaplasia in aged and transgenic mouse prostate tissue with the help of 
PAS staining to detect mucin not normally secreted by the prostate. The second purpose 
was to test and validate an immunohistochemistry protocol to detect PI15 in mouse 
prostate tissue.  
 
The first sign of metaplasia in the epithelial cells is the increase in size. They appear 
much taller than in other glands where the goblet cells cannot be seen. In addition, the 
nuclei are oval shaped. This is very prominent in the tallest and most altered epithelial 
cells. Additionally, goblet cell metaplasia is occurring in several glands in the same area 
in all of the studied samples, which means that the metaplasia has spread from one 
gland to another. This is shown in figure 9A (page 31), where four glands with goblet 
cell metaplasia can be seen, all very close to one another.  
 
The goblet cells often appear close to other goblet cells in the epithelium. This indicates 
that the metaplasia starts from one or more focal points and starts spreading from there. 
This can be seen clearly in figure 9B (page 31), in which the black arrows show goblet 
cells, but in the same gland there are also normal epithelial cells (white arrows). The 
goblet cells and the abnormal epithelial cells are only in the upper part of the gland, 
whereas the bottom is still mostly normal.  
 
The more goblet cells there are in the epithelium, the taller the epithelial cells seem to 
be. In figure 8D (page 30), there is only a small amount of goblet cells and the epithelial 
cells are not much taller than normal, whereas in figures 7D, 9A and 9B (pages 29 and 
31) there is a larger amount of goblet cells in most of the visible glands and the epitheli-
um is also much taller. This, again, indicates that the more the cells are altered in the 
tissue, the more goblet cells appear and the more prominent the metaplasia is.  
 
Even a small amount of goblet cells is enough to stain the lumen in the gland much 
darker than in the glands nearby. In figure 9B (page 31), there are two glands with dark-
er lumen than in the other two visible in the figure, but in the lower gland there are only 
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a few small goblet cells visible and yet the lumen in still much darker than in the two 
normal glands. This indicates that either the small amount of goblet cells have secreted 
a large amount of mucin to the lumen and it is enough to stain it as dark as the mucin 
still inside the goblet cells in the epithelium or most of the goblet cells are in other parts 
of the gland and not visible in the section shown.  
 
Mucinous metaplasia has been previously found in the dorsolateral lobe of the mouse 
prostate. This study, however, did not separate goblet cells in the metaplasia, but it only 
referred to tall columnar cells that secrete mucin. (Suwa et al. 2002.) The goblet cells 
appear close to the urethra, in either the ventral or dorsal lobe in the studied tissues so 
the results show some similarity to the study by Suwa et al. (2002).  
 
No clear difference between the goblet cells in transgenic and wild type mouse prostate 
tissues is found, at least in the studied tissues. Both secrete the mucin to the lumen and 
so stain it darker in the PAS staining. They are similar in size and shape, and the epithe-
lial cell metaplasia seems to be of similar structure as well. They were all located close 
to the urethra, mostly in the same lobes. The only varieties in the lobes were between 
two transgenic mice.  
 
To study goblet cell metaplasia further, more samples should be examined to see exact-
ly which lobe or lobes the metaplasia occurs in. Possibly study a bit younger mice as 
well to see how the metaplasia starts and which processes initiate the metaplasia in the 
first place. Further down the line, it should be examined in human prostate tissue in mu-
cinous metaplasia as well as in mucinous prostate cancer.  
 
As Gibbs et al. (2008) said, PI15 is expressed in the glandular structure of the prostate. 
No big difference is found in the expression of PI15 between formalin and the PAXgene 
fixation, especially between the larger magnifications. The small difference in the visi-
bility could have been caused by the different thickness of the sections or the actual 
fixative. Formalin is known to cross-link some molecules in the tissue (Jackson & 
Blythe 2013, 390), which is why the antigen retrieval is needed. The PFPE processing 
protocol does not always require antigen retrieval for some antigens (Kap et al. 2011), 
which could also explain the small difference in results between these two fixatives. 
PI15 might still require antigen retrieval, but the antigens in the tissue could be easier 
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accessible and the antigen retrieval could bring out the antigens slightly better in the 
PAXgene fixed tissues when compared to formalin fixed tissues.  
 
The larger difference will more likely be found in the DNA and RNA extraction results.  
Thus, the selection on which fixation method to use with PI15 expression should mainly 
be based on the extraction results and whether it is worth the much higher price rather 
than the IHC staining results, at least in the case of PI15.  
 
As for choosing the best buffer to use with PI15, it was clearly better visible in the pH 9 
Tris-EDTA buffer. PI15 can be seen in the lumen of the glands in both buffers (figures 
10 and 11 on pages 33 and 34) but it is much more prominent in the lining of the epithe-
lial cells in the tissues where pH 9 Tris-EDTA buffer was used to retrieve the antigens.  
 
To perfectly optimise the PI15 staining method, it should be tested with equally thick 
sections from both fixation methods to see if there is a critical difference. In addition, 
the DNA and/or RNA should be extracted and the results evaluated. When the staining 
method has been optimised, it should be examined in transgenic mice prostate as well. 
Then, sometime in the future when it has been researched further, it should be tested in 
human prostate tissues as well and whether it can be utilised in prostate cancer diagno-
sis or whether PI15 has a role in prostate cancer development.  
 
When dealing with animal tissue, the ethics of using them must always be considered. 
The studied tissues were received fixed in containers and the dissection process was 
done elsewhere. The animals were treated and euthanized according to the legislations 
and regulations on using animals in research. 
 
To conclude, the purpose of the study was mostly accomplished. Goblet cell metaplasia 
was largely assessed in both transgenic and wild type prostate tissue and the staining of 
PI15 were tested out with both buffers and fixation methods. The original purpose was 
to also examine if the staining of PI15 is altered in transgenic mouse prostate, as well as 
to assess the staining in human prostate tissue, both of which were left out of this study 
due to time constraints. 
 
As miR-32 is a possible contributor to prostate cancer (Latonen 2014), these results 
could benefit the research in that area since miR-32 transgenic mice were studied. These 
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results can also be used in studying goblet cell and mucinous metaplasia, and, sometime 
further down the line, maybe help finding what initiates the metaplasia. As for PI15, the 
results could help the research on whether or not it has a part in prostate cancer devel-
opment or initiation. 
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APPENDICES 
Appendix 1. Solutions 
 
solution manufacturer 
70 % EtOH 
diluted from absolute ethanol: 3500 ml of ethanol to 1500 ml of 
distilled H2O 
96 % EtOH Ethanol 96 % vol (VWR Chemicals) 
Absolute EtOH Ethanol absolute (VWR Chemicals) 
Xylene Technical Xylene (VWR Chemicals) 
Paraffin Histoplast (Thermo Scientific) 
n-Hexane n-Hexane for HPLC (VWR Chemicals) 
Mayer Haematoxylin Histolab Mayers HTX 
Eosin Histolab Eosin 0.2 % 
Schiff’s reagent Schiff's reagent for microscopy (Merck) 
PI15 
Rabbit Polyclonal antibody to Protease Inhibitor (peptidase in-
hibitor 15) TA308594 (OriGene Technologies) 
Antibody diluent ImmunoLogic Normal Antibody Diluent 
UIP Max 
Histofine Simple Stain MAX PO (MULTI) Universal Immuno-
peroxidase Polymer Anti-Mouse and -Rabbit 
ImmPACTTM DAB 
ImmPACTTM DAB Peroxidase Substrate (Diluent and Chromo-
gen concentrate) SK-4105 (Vector Laboratories) 
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Appendix 2. Buffers 
 
pH 9 Tris-EDTA buffer 
0.05 M Tris (Sigma) 
0.001 M EDTA Titriplex III (Merck) 
pH of 9.0 with 2 M hydrochlorid acid 
0.05 % Tween 20 (Sigma) 
 
pH 6 Citrate buffer 
0.01  M Sodium Citrate  
pH of 6.0 with 2 M HCl 
0.05 % Tween 20 (Sigma) 
 
10x TBS 0.5 % Tween 
0.2 M Tris (Trizma base) (Sigma) 
1.5 M Sodium Chloride (J. T. Baker) 
pH of 7.6 with 37 % hydrochloric acid 
0.5 % Tween 20 (Sigma) 
 
 
